[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Polypid Ltd (PYPD)

Polypid Ltd (PYPD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,424
  • Shares Outstanding, K 19,083
  • Annual Sales, $ 0 K
  • Annual Income, $ -34,170 K
  • EBIT $ -33 M
  • EBITDA $ -32 M
  • 60-Month Beta 1.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.22

Options Overview Details

View History
  • Implied Volatility 274.35% (+22.89%)
  • Historical Volatility 115.61%
  • IV Percentile 45%
  • IV Rank 35.17%
  • IV High 723.39% on 03/12/26
  • IV Low 30.74% on 03/13/26
  • Expected Move (DTE 25) 1.31 (32.73%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 85
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 2,077
  • Open Int (30-Day) 1,536
  • Expected Range 2.69 to 5.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.34
  • Number of Estimates 2
  • High Estimate $-0.32
  • Low Estimate $-0.36
  • Prior Year $-0.78
  • Growth Rate Est. (year over year) +56.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.65 +8.49%
on 07/22/26
5.73 -30.89%
on 07/17/26
-0.79 (-16.63%)
since 06/26/26
3-Month
3.65 +8.49%
on 07/22/26
5.73 -30.89%
on 07/17/26
-0.62 (-13.54%)
since 04/27/26
52-Week
3.06 +29.41%
on 10/10/25
5.73 -30.89%
on 07/17/26
+0.28 (+7.61%)
since 07/25/25

Most Recent Stories

More News
PolyPid Q1 Earnings Call Highlights

PolyPid (NASDAQ:PYPD) said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for...

PYPD : 3.98 (+2.05%)
Q1 Virtual Investor Summit: On-Demand Presentations Now Live

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors...

SNANF : 0.2200 (+0.27%)
BRNS : 0.6000 (-0.33%)
FEMY : 3.18 (-14.26%)
PERF : 1.9200 (-0.52%)
DRTS : 12.25 (-2.00%)
GIFT : 0.9001 (+0.01%)
ROYIF : 0.0714 (-4.80%)
ZCAR : 0.1222 (-1.61%)
CLNN : 5.36 (-0.56%)
MIND : 5.40 (-2.70%)
PYPD : 3.98 (+2.05%)
TOVX : 0.2106 (-5.52%)
PolyPid Ltd. to Present at the Q1 Investor Summit Virtual Conference on March 11th, 2025

NEW YORK, NY / ACCESS Newswire / February 27, 2025 / The Investor Summit Group (ISG), today announced that Ori Warshavsky, Chief Operating Officer - US Operations and Jonny Missulawin, Chief Financial...

PYPD : 3.98 (+2.05%)
PolyPid Ltd. Announces Research Collaboration with ImmunoGenesis to Enhance Immunotherapy for Solid Tumors

PolyPid collaborates with ImmunoGenesis to enhance solid tumor treatment using innovative drug delivery technologies.Quiver AI SummaryPolyPid Ltd. has announced a collaboration with ImmunoGenesis, Inc....

PYPD : 3.98 (+2.05%)
PolyPid Ltd. Faces Nasdaq Non-Compliance Notification Due to Stockholders' Equity Shortfall

PolyPid Ltd. faces Nasdaq non-compliance but has potential funding options to regain stockholder equity requirements.Quiver AI SummaryPolyPid Ltd., a late-stage biopharma company focused on improving surgical...

PYPD : 3.98 (+2.05%)
PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million in Upfront and Milestone Payments, Plus...

PYPD : 3.98 (+2.05%)

Business Summary

PolyPid Ltd. is a pharmaceutical company. It discovers, develops and commercializes antibiotic drugs for the prevention of surgical infections. The company's product candidate includes D-PLEX100, BONYPID-1000 and BONYPID-500 which are in clinical stage. PolyPid Ltd. is based in Petach Tikva, Israel.

See More

Key Turning Points

3rd Resistance Point 4.59
2nd Resistance Point 4.45
1st Resistance Point 4.17
Last Price 3.98
1st Support Level 3.75
2nd Support Level 3.61
3rd Support Level 3.33

See More

52-Week High 5.73
Fibonacci 61.8% 4.71
Fibonacci 50% 4.39
Fibonacci 38.2% 4.08
Last Price 3.98
52-Week Low 3.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.